![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Laurus Labs Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Oxaliplatin, Process 2, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2011-357 - Rev 03
This Chemical Type CEP, issued on January 19, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2017 associated with this CEP further emphasizes